A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

被引：3

作者：

Pemmaraju, Naveen

Marconi, Giovanni

Todisco, Elisabetta

Montesinos, Pau

Lane, Andrew A.

Sweet, Kendra

Wang, Eunice S.

Deconinck, Eric

Rizzieri, David A.

Walter, Roland B.

Aribi, Ahmed

Lebon, Delphine

Levy, Moshe Y.

Mazzarella, Luca

Martinelli, Giovanni

Gigli, Federica

Erba, Harry P.

Acuna-Cruz, Evelyn

Konopleva, Marina

Kantarjian, Hagop

Sloss, Callum M.

Wang, Jiuzhou

Malcolm, Kara E.

Zweidler-McKay, Patrick A.

DeAngelo, Daniel J.

Daver, Naval

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Ist Seragnoli, Bologna, Italy

[3] European Inst Oncol IRCCS, Div Onco Hematol, Milan, Italy

[4] Hosp Univ & Politecn La Fe, Valencia, Spain

[5] Dana Farber Boston Childrens Canc & Blood Disorde, Dept Med Oncol, Boston, MA USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[7] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[8] Besancon Univ Hosp, Clin Hematol, Besancon, France

[9] Duke Univ Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Med, Durham, NC USA

[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[11] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA USA

[12] CHU Amiens, Hematol Dept, Amiens, France

[13] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[14] European Inst Oncol, Milan, Italy

[15] Inst Hematol LeA Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[16] European Inst Oncol, Milan, Italy

[17] Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[19] ImmunoGen, Waltham, MA USA

[20] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146681

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4429

引用

页数：10

共 50 条

[1] Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Pemmaraju, Naveen
Martinelli, Giovanni
Todisco, Elisabetta
Lane, Andrew A.
Acuna-Cruz, Evelyn
Deconinck, Eric
Wang, Eunice S.
Sweet, Kendra
Rizzieri, David A.
Marconi, Giovanni
Mazzarella, Luca
DeAngelo, Daniel J.
Montesinos, Pau
Gigli, Federica
Erba, Harry P.
Konopleva, Marina
Kantarjian, Hagop
Walter, Roland B.
Aribi, Ahmed
Lebon, Delphine
Levy, Moshe Y.
Sloss, Callum M.
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
Daver, Naval
BLOOD, 2021, 138
[2] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Pemmaraju, Naveen
Martinelli, Giovanni
Todisco, Elisabetta
Lane, Andrew A.
Acuna-Cruz, Evelyn
Deconinck, Eric
Wang, Eunice S.
Sweet, Kendra L.
Rizzieri, David A.
Mazzarella, Luca
DeAngelo, Daniel J.
Montesinos, Pau
Tarella, Corrado
Erba, Harry P.
Konopleva, Marina
Kantarjian, Hagop M.
Sloss, Callum M.
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
Daver, Naval
BLOOD, 2020, 136
[3] Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models
Zhang, Qi
Cai, Tianyu
Han, Lina
Kuruvilla, Vinitha Mary
Adams, Sharlene
Callum, Sloss M.
Harutyunyan, Karine
Lane, Andrew A.
Kovtun, Yelena
Daver, Naval G.
Pemmaraju, Naveen
Mckay, Patrick Zweider
Konopleva, Marina Y.
BLOOD, 2018, 132
[4] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Daver, Naval G.
Montesinos, Pau
DeAngelo, Daniel J.
Wang, Eunice S.
Papadantonakis, Nikolaos
Deconinck, Eric
Erba, Harry P.
Pemmaraju, Naveen
Lane, Andrew A.
Rizzieri, David A.
Sweet, Kendra L.
Martinelli, Giovanni
Tarella, Corrado
Todisco, Elisabetta
Konopleva, Marina Y.
Sloss, Callum M.
Culm-Merdek, Kerry
Zweidler-McKay, Patrick A.
Kantarjian, Hagop M.
BLOOD, 2019, 134
[5] A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
Daver, Naval Guastad
Montesinos, Pau
DeAngelo, Daniel J.
Wang, Eunice S.
Todisco, Elisabetta
Tarella, Corrado
Martinelli, Giovanni
Erba, Harry Paul
Deconinck, Eric
Sweet, Kendra L.
Walter, Roland B.
Levy, Moshe Yair
Pemmaraju, Naveen
Lane, Andrew A.
Rizzieri, David
Konopleva, Marina
Sloss, Callum Mortimer
Wang, Jiuzhou
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Daver, Naval G.
Montesinos, Pau
Deangelo, Daniel J.
Wang, Eunice S.
Papadantonakis, Nikolaos
Todisco, Elisabetta
Sweet, Kendra L.
Pemmaraju, Naveen
Lane, Andrew A.
Torres-Minana, Laura
Thompson, James E.
Konopleva, Marina Y.
Sloss, Callum M.
Watkins, Krystal
Bedse, Gaurav
Du, Yining
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
Kantarjian, Hagop M.
LANCET ONCOLOGY, 2024, 25 (03): : 388 - 399
[7] A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Kovtun, Yelena
Jones, Gregory E.
Adams, Sharlene
Harvey, Lauren
Audette, Charlene A.
Wilhelm, Alan
Bai, Chen
Rui, Lingyun
Laleau, Rassol
Liu, Fenghua
Ab, Olga
Setiady, Yulius
Yoder, Nicholas C.
Goldmacher, Victor S.
Chari, Ravi V. J.
Pinkas, Jan
Chittenden, Thomas
BLOOD ADVANCES, 2018, 2 (08) : 848 - 858
[8] IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS
Kovtun, Y.
Jones, G.
Harvey, L.
Rui, L.
Audette, C.
Liu, F.
Bai, C.
Wilhelm, A.
Yoder, N. C.
Adams, S.
Goldmacher, V. S.
Chari, R.
Chittenden, T.
HAEMATOLOGICA, 2016, 101 : 222 - 222
[9] Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia
Daver, Naval
Montesinos, Pau
Altman, Jessica K.
Wang, Eunice S.
Martinelli, Giovanni
Roboz, Gail J.
Begna, Kebede
Vyas, Paresh
Lunghi, Monia
Platzbecker, Uwe
Burke, Patrick W.
Walter, Roland B.
Advani, Anjali S.
Garciaz, Sylvain
Gastaud, Lauris
Sallman, David A.
Pemmaraju, Naveen
Torres, Laura
Abaza, Yasmin
Chan, Onyee
Kantarjian, Hagop M.
Oshrine, Benjamin
Du, Yining
Malcolm, Kara
Sweet, Kendra
BLOOD, 2023, 142
[10] A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.
Daver, Naval Guastad
Wang, Eunice S.
Sweet, Kendra L.
Montesinos, Pau
Erba, Harry Paul
DeAngelo, Daniel J.
Sloss, Callum Mortimer
Wang, Jiuzhou
Malcolm, Kara E.
Zweidler-McKay, Patrick A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →